Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

Hong Wu(Hangzhou Center for Disease Control and Prevention), Qingsong Liu(Medical College of Wisconsin)
Oncotarget
September 5, 2015
Cited by 46


Related Papers